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Abstract
Periodontitis is a biofilm-induced inflammatory disease characterized by dysbiosis of the 
commensal periodontal microbiota. It is unclear how natural regulation of inflammation affects the 
periodontal biofilm. Promoters of active resolution of inflammation including Resolvin E1 (RvE1) 
effectively treat inflammatory periodontitis in animal models. The goals of this study were 1) to 
compare periodontal tissue gene expression in different clinical conditions, 2) to determine the 
impact of local inflammation on the composition of subgingival bacteria, and 3) to understand how 
inflammation impacts these changes. Two clinically-relevant experiments were performed in rats: 
prevention and treatment of ligature-induced periodontitis with RvE1 topical treatment. The 
gingival transcriptome was evaluated by RNA-seq sequencing of mRNA. The composition of the 
subgingival microbiota was characterized by 16S rDNA sequencing. Periodontitis was assessed by 
bone morphometric measurements and histomorphometry of block sections. H&E and, tartrate 
resistant acid phosphatase staining were used to characterize and quantify inflammatory changes. 
RvE1 treatment prevented bone loss in ligature induced periodontitis. Osteoclast density and 
inflammatory cell infiltration in the RvE1 groups were lower than those in the placebo group. 
RvE1 treatment reduced expression of inflammation-related genes returning the expression profile 
to one more similar to health. Treatment of established periodontitis with RvE1 reversed bone loss, 
reversed inflammatory gene expression and reduced osteoclast density. Assessment of the rat 
subgingival microbiota after RvE1 treatment revealed marked changes in both prevention and 
treatment experiments. The data suggest that modulation of local inflammation has a major role in 
shaping the composition of the subgingival microbiota.
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Introduction
Chronic periodontitis is a multifactorial inflammatory disease with high prevalence in many 
populations (1). Periodontitis is characterized by dysbiosis of the commensal microbiota 
associated with inflammation; however, the temporal sequence and interplay between 
specific bacteria and inflammation has not been described (2). Mechanical debridement has 
long been the standard treatment for periodontitis (3). It is believed that removal of 
subgingival plaque is sufficient to reduce the inflammatory response stimulated by bacteria 
and stop tissue destruction. However, subgingival debridement has limitations and cleansing 
of diseased areas is often incomplete (4). Regardless of completeness of debridement, 
bacteria grow back gradually after mechanical therapy in the absence of further treatment or 
maintenance and the disease associated hyper-inflammation rapidly returns (5). Adjunctive 
use of antibiotics improves clinical outcomes, but antibiotic resistance and other side effects 
are always a concern (6).
In recent years, it has become apparent that susceptibility to and pathogenesis of periodontal 
disease are mediated by the host (7–10). Subjects with severe periodontitis exhibit 
measurable excess inflammation that includes cytokine production (11) and oxidative stress 
(12, 13), and the presence of inflammation predicts diseases progression (14, 15). Early 
studies attempting to control the host inflammatory response have shown that COX 
inhibitors slow disease progression without modifying bacterial composition in animal 
studies (16–18) and clinical studies (19–21), but the long term use of cyclooxygenase 
inhibitors has serious side effects, such as increased risks of gastrointestinal tract bleeding 
and cardiovascular diseases (22), that preclude their prolonged clinical use for periodontitis. 
There is a critical need to develop rational and safe host modulation therapies to prevent and 
treat periodontitis.
Specialized pro-resolving mediators (SPMs), including lipoxins, resolvins, protectins, and 
maresins, play an important role in the resolution phase of acute inflammation (23). In the 
resolution phase, SPMs actively reduce neutrophil infiltration, promote neutrophil apoptosis 
(24), and recruit non-phlogistic macrophages to clear apoptotic neutrophils and remaining 
bacteria signaling through specific G protein-coupled receptors. To complete the resolution 
phase, macrophages are themselves cleared by efferocytosis (25, 26). SPMs, which are 
inflammation regulators rather than inhibitors, can replace NSAIDs in treating inflammation 
by actively inducing and enhancing resolution of inflammation. Resolvin E1 (RvE1), one of 
the resolvins derived from the omega-3 polyunsaturated fatty acid, eicosapentaenoic acid 
(EPA), has been shown to be effective in treating periodontitis in animals (27). RvE1 
promotes inflammation resolution (28) and regulates bone remodeling (29, 30). In rabbits, 
local application of RvE1 prevents the onset of periodontitis (31) and promotes regeneration 
of the periodontium (27). An interesting observation in these studies was the apparently 
spontaneous disappearance of the periodontal pathogen P. gingivalis without the use of 
mechanical or antimicrobial therapy (27). The dynamics of microbial shifts resulting from 
resolution of inflammation that permit tissue regeneration following RvE1 application are 
not clear.
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The goal of this study was to begin to understand the temporal dynamics of inflammation 
induced dysbiosis of the periodontal microbiota. To accomplish this goal, periodontitis was 
induced in the rat using ligatures to observe changes in the microbiota and the host without 
the addition of exogenous pathogens. Global differential gene expression in periodontal 
tissues was evaluated in health, disease and after treatment with RvE1 to provide an 
unbiased assessment of inflammatory changes. In parallel, 16S rDNA sequencing was 
employed in the same experiments to determine the impact of local inflammation on the 
composition of subgingival bacteria. The data suggest a dynamic, temporal interaction 
between local inflammation and the composition of the periodontal microbiota.
Materials and Methods
Experimental Periodontitis
The impact of inflammation on the subgingival microbiota in ligature induced periodontitis 
in the rat was assessed in two separate experiments: prevention of ligature induced 
periodontitis (prevention experiment) and treatment of established periodontitis (treatment 
experiment). The protocols were approved by Institutional Animal Care and Use Committee 
(IACUC) of the Forsyth Institute. Six-week old male Wistar rats (weight 180–200 g, Charles 
River Laboratories, Wilmington, MA) were maintained in a controlled temperature (22°C to 
25° C) and dark/light cycle (12/12 hours) facility. Rats received standard laboratory chow 
diet and water ad libitum. Rats were sedated with 2–3% isoflurane and anesthetized with 
ketamine (80mg/kg, intraperitoneally) and xylazine (16 mg/kg, intraperitoneally) for all 
procedures. In the prevention experiment, 16 rats were divided into four groups (no ligature 
(health), ligature + vehicle (disease), ligature + RvE1 (0.1μg/μl), ligature + RvE1 (0.5μg/
μl)). Two μl vehicle alone, RvE1 at 0.1μg/μl (0.28mM), or 0.5μg/μl (1.4mM) was topically 
applied with a Hamilton syringe (25G needle, 5μl syringe) three times a week (M, W, F). 5–
0 silk ligatures were placed subgingivally on the maxillary right and left second molars of all 
rats. The experimental period was 4 weeks. Ligatures were checked at every application. 
RvE1 (FW: 350.5; purity > 97%, λmax: 272 nm) was obtained from Cayman Biochemicals. 
Untreated, unligatured animals were sacrificed to obtain healthy tissue samples. Subgingival 
plaque samples were collected on day 0, 7, 10, 14, 17, 21, 24, and 28. Rats were euthanized 
by CO2 inhalation; gingival tissue and maxillae were harvested.
In the treatment experiment, 18 rats were divided into four groups (no ligature (health): n=6, 
ligature alone: n=6, ligature + vehicle: n=3, ligature + RvE1: n=3). 3–0 silk ligatures were 
placed subgingivally on the maxillary right and left second molars at baseline. The entire 
experimental period lasted six weeks beginning with a three-week disease induction phase 
followed by the subsequent three-week treatment phase. Six rats in the no ligature group 
provided healthy tissue. At the end of the disease induction phase (21st day), the six rats in 
the ligature alone group were sacrificed to quantify the amount of disease induced. During 
the treatment phase (weeks four to six), 4 μl of a 0.25 μg/μl solution of RvE1 (0.7mM) was 
topically applied to ligated teeth (RvE1 group) every other day. 4 μl application of vehicle 
alone following the same regimen served as the treatment control. The dose was based on 
the estimated optimal dose determined in the prevention experiment. At the end of week six, 
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remaining rats were sacrificed. Subgingival plaque samples were collected on day 0, 8, 12, 
16, 20, 24, 28, 32, 36, and 40.
Morphometric analysis
The dissected maxillae were defleshed, stored in 0.3% hydrogen peroxide for 24 hours and 
dried completely before methylene blue staining. Images (0.63X10) were taken under 
dissecting microscope (Axio observer A1, ZEISS) using AxioVision 4.8 software. The area 
of exposed root surface of three maxillary molars was measured buccally and palatally (Fig. 
1). The distance between the alveolar bone and cementoenamel junction (CEJ) was 
measured at nine sites as indicated of three maxillary molars at the buccal site and the palatal 
site along the axis of the tooth root (Fig. 1) using computer software (ImageJ).
Histomorphometry
Half of the maxilla was decalcified in 20 volumes of 10% EDTA and the decalcification was 
confirmed by calcium oxalate precipitation. Specimens were dehydrated in increasing 
concentrations of ethanol sequentially, and embedded in paraffin. Serial mesiodistal sections 
(6 mm) parallel to the long axis of the teeth were cut and stained with H&E and 
identification of the cellular composition, or tartrate-resistant acid phosphatase to quantify 
osteoclastic activity with light microscopy.
Similar anatomic positions were selected for quantitative measurements and identification of 
samples was masked to avoid bias. The number of neutrophils, lymphocytes and plasma 
cells was counted at 400X. The total number of multinucleated osteoclasts in the 
interproximal bone was counted at 200X and osteoclast density expressed as number of 
osteoclasts per μm2 using computer software (ImageJ).
RNA-Seq and differential expression analysis
Gingival samples were collected from two rats in each group from the prevention experiment 
and processed for RNA sequencing (RNA-Seq) on the Illumina platform. Total RNA was 
extracted from homogenized gingival tissue with an RNeasy® Mini kit (QIAGEN Inc., 
Valencia, CA). RNA quality was assessed with the Agilent RNA 6000 NanoLabChip Kit of 
the Bioanalyzer system (Santa Clara, CA, USA). RNA-Seq cDNA libraries were made using 
the Illumina Truseq stranded mRNA Sample Prep kit and were sequenced using the NextSeq 
v3, 2 x 75 cycle cartridge on a NextSeq sequencer. The RNA-Seq reads were uploaded to the 
Illumina BaseSpace cloud platform (http://basespace.illumina.com) and the RNAExpress 
application was used to align reads to the rat genome (Rattus norvegicus UCSC version rn5), 
calculate read count per gene using the STAR aligner (32), and perform differential gene 
expression analysis with DESeq2 (33). The raw RNA sequencing reads were also submitted 
to the National Center for Biotechnology Information Sequence Read Archive database 
(http://www.ncbi.nlm.nih.gov/Traces/sra/, BioProject number PRJNA321482).
The iPathwayGuide was used to score the biological pathways using impact analysis (34, 
35). Impact analysis uses two types of evidence: i) the overrepresentation of differentially 
expressed (DE) genes in a given pathway and ii) the perturbation of that pathway computed 
by propagating the measured expression changes across the pathway topology. These aspects 
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are captured by two independent probability values, pORA representing the probability of 
obtaining a number of DE genes on the given pathway greater or equal to chance 
observations (36), and pAcc calculated based on the amount of perturbation measured in 
each pathway. pORA and pAcc are then combined in a unique global p-value using Fisher's 
method. This p-value is then corrected for multiple comparisons using the False Discovery 
Rate (FDR) method.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
qRT-PCR was utilized to confirm the results of RNA-seq. A total of 1 μg RNA from each 
sample assessed in RNA-seq was converted to cDNA using a high-capacity cDNA reverse 
transcriptase kit (Applied Biosystems, Grand Island, NY). qRT-PCR was performed using 
primers and TaqMan probes for ten differentially expressed genes (Acp5, Angptl4, Ccl9, 
Cxcl1, Cxcl2, Ide, Il1b, Mmp13, Nfkibia, Rac2) in RNA-seq (Applied Bio-systems, TaqMan 
gene expression assays). β-actin (Actb) was the internal standard amplified using 
preformulated TaqMan probes (Applied Biosystems, Endogenous Control). Quantification 
was performed in an automated thermal cycler (StepOnePlus™ System, Applied 
Biosystems); 50°C for 2 min (one cycle), 95°C for 20 sec (one cycle), 95°C for 1 sec, and 
60°C for 20 sec (40 cycles) and relative expression (2−Δ ΔCT) calculated.
RNA-seq was not performed on samples from the treatment experiment, but qRT-PCR was 
used to assess expression of candidate genes. Total RNA was extracted from homogenized 
gingival tissue with Trizol reagent (Invitrogen, Grand Island, NY). The concentration and 
purity of RNA was estimated spectrophotometrically (ratio of absorbance at 260 and 280 
nm: NanoDrop 2000c, Thermo Fisher Scientific, Waltham, MA). Total RNA was reversely 
transcribed to cDNA and cDNA was quantified following the same protocol utilized in the 
prevention experiment. Three inflammation related genes, Cxcl1 (IL-8 equivalent), Nos2 
(inducible nitric oxide synthase), and Ptgs2 (COX2) were assessed and β-actin (Actb) was 
the internal standard (Applied Bio-systems, TaqMan gene expression assays).
Bacterial DNA extraction and Amplification
Subgingival plaque samples were collected using the tip of a 2-Whiteside scaler (Hu-Friedy, 
Chicago, IL) from the palatal side of the maxillary second molars. DNA was extracted using 
MolYsis Basic (CaerusBio Inc., Downingtown, PA) and QIAamp® mini kits (QIAGEN Inc., 
Valencia, CA). The MolYsis Basic kit excludes DNA of mammalian cells (37, 38). The 
extracted bacterial DNA was amplified with a multiple displacement amplification (MDA) 
kit (GenomiPhi™V3 DNA amplification kit, GE Healthcare Bio-Sciences, Pittsburgh, PA) 
enabling whole genomic amplification of DNA targets (39, 40). The concentration of 
amplified DNA samples was measured with fluorescent nucleic acid stain (Quant-iT™ 
PicoGreen® dsDNA Assay, Life Technologies, Grand Island, NY).
16S rDNA sequencing
The microbial composition of plaque samples (50ng DNA/10μl) was characterized by 
sequencing the hyper-variable V3 and V4 regions of the 16S rDNA gene using the Illumina 
MiSeq® platform. The 2 x 250-bp paired-end sequencing allows the capture of the entire 
440-bp V3-V4 region by merging the read pairs based on the overlap. Successfully merged 
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reads were processed through the QIIME pipeline (41) using a 97% identity threshold and 
the SILVA reference database (SILVA/Greengenes) (42, 43). Taxonomic assignments to 
operational taxonomic units (OTUs) from phylum to genus level were completed through 
QIIME’s use of the given reference database (SILVA/Greengenes) and the UCLUST 
algorithm (44). To understand the diversity and composition of microbial community, further 
analyses included alpha diversity (e.g. richness), beta diversity (weighted UniFrac) (45), 
principal coordinate analysis (PCoA) and relative abundance profiles of microbial 
community in the samples. The relative abundance of taxa was determined by dividing the 
hits of a specific taxon by the total hits of all taxa in the sample.
Statistical Analysis
In the prevention experiment, sample size was calculated based on published data (27) and 
preliminary results. We hypothesized that the change in exposed root surface in disease can 
be prevented 50% by treatment and the clinical effect is the same in the two treatment 
groups. At least three animals per group were needed in order to detect the difference in 
exposed root surface between four groups with 80% power. The sample size in the treatment 
experiment was also calculated based on the preliminary results and the assumption that the 
treatment can regenerate 50% of lost bone surface. At least two animals per group were 
needed to detect the difference in exposed surface between four groups with 80% power. 
Multiple comparisons of bone morphometry, histomorphometry, and relative gene 
expression were analyzed by one-way analysis of variance (ANOVA) and post hoc analysis 
(pairwise t-test). All values are expressed as mean ± standard error of the mean. P-value 
<0.05 was considered statistically significant
For 16S rDNA sequencing experiments, descriptive statistics are presented due to the 
exceptionally large number of potential comparisons. Values are expressed as mean ± 
standard error of the mean.
For RNA-seq, significance of differentially expressed genes was obtained using a threshold 
of 0.6 for absolute log2 expression change and 0.05 (unless otherwise stated) false discovery 
rate, or family-wise error rate (Benjamini–Hochberg procedure). Wald test on logarithmic 
transformed data was used to compare the gene expression level between two groups in each 
comparison. These data were analyzed in the context of pathways obtained from the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database (release 73.0+/0316, March 15) (46, 
47), the gene ontology from the Gene Ontology Consortium database (September 19, 2014) 
(48, 49), miRNAs from the miRBase (release 21) and MicroCosm Targets version 5 
(updated March 2015) databases (50–53), and diseases from the KEGG database (release 
73.0+/0316, March 15) (46, 47). Correlation between mean fold changes of genes in RNA-
seq and mean fold changes of genes in qRT-PCR for each sample was assessed by a 
Spearman rank correlation coefficient.
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Results
RvE1 treatment prevents and reveres alveolar bone loss
Ligature placement induced significant bone loss in both experiments (Fig. 1A, 1B, 1C, 1D). 
In the prevention experiment, prophylactic RvE1 treatment at low and high doses reduced 
alveolar bone loss by 1.51 and 1.73 mm2, respectively (95% confidence interval [CI]= (0.33, 
2.70) and (0.40, 3.06); p=0.02 and 0.01, respectively compared with vehicle control) 
expressed as area of exposed root surface. The distance between the alveolar bone and CEJ 
was reduced by 2.03 and 2.45 mm, respectively (95% CI= (0.27, 3.80) and (0.59, 4.30); 
p=0.02 and 0.01, respectively compared with vehicle control) (Fig. 1A, 1B). In the treatment 
experiment, RvE1 treatment of established periodontitis reversed alveolar bone loss induced 
by ligature placement. Specifically, bone loss expressed as area of exposed root surface was 
reduced by 2.24 mm2 (95% CI= (1.11, 3.37), p=0.002 and by 3.17 mm in distance between 
the alveolar bone and CEJ compared with vehicle (95% CI= (1.69, 4.65), p=0.001, Fig. 1C, 
1D).
RvE1 treatment inhibits inflammation and osteoclast activity
Ligature placement significantly increased inflammatory cell infiltration and osteoclast 
density (Fig. 2A, 2B; Supplemental Fig. 1B, 1D). Prophylactic RvE1 treatment significantly 
reduced inflammatory cell infiltration (Supplemental Fig. 1B) and osteoclast density (Fig. 
2A) compared to vehicle at both doses. There was no significant difference between the two 
RvE1 doses (ANOVA; Fig. 2A).
In the treatment experiment, the mean count of inflammatory cells in the RvE1 group 
trended lower (p=0.57) (Supplemental Fig.1D). RvE1 treatment significantly reduced 
osteoclast density compared to vehicle (Fig. 2B).
Impact of RvE1 treatment on periodontal tissue gene expression
Fig. 3A, which illustrates the top 200 differentially expressed genes in the heat map 
comparing periodontitis versus health, and RvE1 versus periodontitis treatment at low and 
high doses in the prevention experiment, reveals that prophylactic RvE1 treatment appeared 
to prevent the gene expression pattern of the diseased state, being very similar to the 
expression pattern of health. A clear dose response was observed. Further analyses were 
done with the high RvE1 dose (0.5 μg/μl).
Twenty nine differentially expressed genes exhibited an expression fold change ≥ 2^0.6 
(adjusted p-value <0.1). All genes exhibited opposite expression patterns with RvE1 
treatment (Fig. 3B). Most genes were identified as inflammatory response genes (Ccl3, 
CxCl1, Cxcl2, Il1b, Il18bp, Mmp3, Mmp10, Mmp13, Nfkbia) or bone resorption associated 
genes (Acp5, Ccl9).
There were six significant biological pathways identified as associated with the observed 
changes (Table I). These KEGG pathways were related to the infection response (chemokine 
signaling pathway, Chagas disease), bone resorption (rheumatoid arthritis, osteoclast 
differentiation) and metabolic activity (pancreatic secretion, bile secretion). Five genes 
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(Ccl3, Ccl9, Cxcl1, Cxcl2, Rac2) belonging to chemokine signaling pathway were 
upregulated in the diseases state, but were downregulated following RvE1 treatment. RvE1 
treatment downregulated bone resorption pathway gene expression (Acp5, Ccl3, Mmp3, 
Trem2) and pancreatic secretion pathway gene expression (Sctr).
Comparing mean fold changes (log2) of 10 selected genes in RNA-seq and qRT-PCR, 10 
genes have similar expression patterns (Table II). Gene expression assessed by RNA-seq and 
qRT-PCR are comparable (Spearman's rho = 0.88, P = 0.0000).
In the treatment experiment, three candidate genes were assessed by qRT-PCR. Cxcl1, Nos2, 
and Ptgs2 in the RvE1 group were lower than controls, and RvE1 treatment significantly 
reduced gene expression level of Cxcl1 compared to vehicle application (p=0.02) (Fig. 3C).
RvE1 treatment and the subgingival microbiota
Considering the variation in relative abundance and limited sample size, a threshold p-value 
of 0.3 (Student’s t-test) was chosen to screen the potential genera representing subgingival 
microbiota in different groups in an attempt to eliminate background noise. Results are 
presented at the genus level, since the threshold of 97% sequence similarity was used to 
assign OTU.
The composition of subgingival microbiota at baseline was markedly different from disease 
(Fig. 4A). One genus, Rothia, was dominant with consistent relative abundance in all the 
samples at baseline (59.32 ±19.20 %). After disease induction, increased diversity was 
observed with a loss of Rothia (53.97%) and a loss of Granulicatella (3.0%) and 
Corynebacterium (2.9%) and overgrowth and emergence of Streptococcus (39.07%), 
Enterococcus (5.47%), Bifidobacterium (6.4%) and Blautia (4.23 %), among others 
including Lactobacillus (0.88%).
In the prevention experiment, RvE1 treatment (0.1μg/μl and 0.5μg/μl) altered the mean 
relative abundance of each genus measured compared to vehicle on day 14 (Fig. 5A, 5B) and 
day 28 (Fig. 5C, 5D). By day 28, 0.1μg/ml RvE1 reduced overgrowth of Lactobacillus, but 
not of Bifidobacterium; it also did not reverse the loss of the dominant species in health, 
Rothia. At day 28 with 0.5μg/ml RvE1, the dominance of Rothia had re-emerged, 
Lactobacillus was further reduced, Bifidobacterium overgrowth was reduced and the 
complexity of the flora was simpler (Supplemental Fig. 2). The compositional shifts in 
subgingival alpha and beta diversity were associated with different degrees of inflammation 
in the local periodontal environment (Supplemental Fig. 2). In general, the relative 
abundance of most of these genera in the RvE1 groups was lower than the disease group. 
Data are expressed as relative abundance; direct comparisons of bacterial numbers were not 
made.
In the treatment experiment, there was a clear shift in the subgingival microbiota following 
ligature placement (Fig. 4A). Two genera, Streptococcus (overgrowth) and Rothia (loss), 
exhibited the largest changes in mean relative abundance during the disease induction phase. 
In the treatment phase, the subgingival microbiota shift was compared between the ligature 
+ RvE1 group and the ligature + vehicle group. Four genera (Enterococcus, Veillonella, 
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Allobaculum, Lactobacillus) demonstrated the greatest shifts on day 32. On day 40, eleven 
genera (Coprococcus, Lactobacillus, Blautia, Sutterella, Veillonella, Streptococcus, 
Corynebacterium, Collinsella, Facklamia, Dorea, Aggregatibacter) exhibited the largest 
shifts (Fig. 4B, 4C). Although there was a trend for returning the microbiota to one more 
associated with health that was consistent with the clinical outcome (reversal of bone loss 
and reduced inflammation), the shift was incomplete in the timeframe of the experiment.
Discussion
It is well established that RvE1 inhibits neutrophil infiltration, induces neutrophil apoptosis, 
attracts non-phlogistic macrophages that phagocytize apoptotic neutrophils and bacteria and 
clear the chronic inflammatory lesions through efferocytosis (23). Release of pro-
inflammatory cytokines and chemokines is reduced during the resolution of inflammation 
(23, 28). Resolvins provide a feed forward, receptor agonist driven enhancement of 
resolution of inflammation, not inhibition of inflammation as with NSAID inhibition of 
COX or receptor antagonists. The present study demonstrates, in separate experiments, that 
RvE1 application prevents and successfully treats ligature induced periodontitis in the rat. 
Treatment was associated with regeneration of alveolar bone lost to periodontitis, inhibition 
of inflammation and osteoclast activity, and downregulation of inflammation associated 
genes in gingival tissues. We also demonstrate, to our knowledge for the first time, that shifts 
in the subgingival microbiota induced with ligature are markedly changed by control of local 
inflammation. The experiments tested the hypothesis that inflammation plays a major role in 
the induction and maintenance of dysbiosis. We demonstrate that regulation of inflammation 
with resolvin E1 has a significant impact on gingival gene expression and subgingival 
bacterial composition that is coincident with prevention and treatment of disease.
Periodontitis is a disease of microbial dysbiosis (54, 55). Shifts in the composition and 
bacterial counts within the subgingival microbiota have been associated with periodontal 
disease in myriad studies (56–58). From an ecological point of view, in active periodontitis 
many disease-associated species overgrow by obtaining required nutrients from the inflamed 
environment. Therefore, the diseased microbial community is more diverse at any one site 
(alpha diversity) than is the healthy microbial community. The microbial community of 
samples from different disease sites becomes more similar (beta diversity) compared to the 
microbial community of different healthy samples (59–63). The ecological plaque 
hypothesis proposed by Marsh (64, 65) emphasizes a direct link between local 
environmental conditions and the activity and composition of the microbial community. The 
changes in local environment trigger the changes in microbiota, and vice versa.
Inflammation and change of local environment appear to drive the shifts in subgingival 
microbiota (Figs. 4, 5). However, this does not minimize the role of overgrowth of specific 
bacteria and expression of virulence factors that coincide with inflammation. It has been 
recently demonstrated in a bacterial transcriptomic analyses that putative virulence factors 
are upregulated by bacteria (both putative pathogens and health associated commensals) in 
progressing periodontitis sites (66, 67). Bacteria are necessary to induce periodontitis in the 
ligature model (68), but the change of microbiota in different clinical conditions has never 
been explored. Previously reported studies in rabbits show that microbial shifts are prevented 
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and reversed by RvE1, but these studies are indirect using probes to human microorganisms 
(27). The results of the unbiased characterization of the microbiota of the rat performed here 
emphasize the differences between human and rat microbiota associated with health and 
disease. This study did not aim to investigate the roles of these genera in pathogenesis of 
experimental periodontitis in rats.
RvE1 treatment induced marked changes in the microbiota. The compositional shifts in 
subgingival alpha and beta diversity were associated with different degrees of inflammation 
in the local periodontal environment (Supplemental Fig. 2). The data suggest that most of 
these shifts are driven by the changes in inflammation, since RvE1 was the only treatment 
variable and it is known to have no direct antimicrobial activity (31, 69). Since experimental 
periodontitis was induced consistently in these animals, the shifts in subgingival microbiota 
and the emergence of new bacteria can be attributed to changes in inflammation. There are 
at least two possible mechanisms: (i) RvE1 regulates killing activity of immune cells; and/or 
(ii) resolution of inflammation alters the local environment removing the source of nutrients 
for certain bacteria, particularly those associated with periodontitis. Asaccharolytic bacteria 
that comprise periodontitis associated bacteria depend on peptides and other metabolites 
derived from host-tissue degradation as nutrients to survive (7, 10). The composition of 
metabolites in periodontal tissue fluid is associated with periodontal inflammation (7, 71, 
72). The impact of RvE1 on phagocytosis and production of reactive oxygen species (ROS) 
by immune cells has been demonstrated (24, 69, 70). Taken together, the data suggest that 
inflammation regulated by RvE1 leads to the observed shifts in microbial composition.
The pattern of differential gene expression in rat periodontal tissue between periodontitis 
and health is similar to that between the periodontitis group and the healthy group in human 
gingiva (73). In addition to the down-regulation of immune response stimulation related 
genes (Ccl3, CxCl1, Cxcl2, Il1b), immune response inhibition genes (Il18bp, Lilrb4, Nfkbia) 
were also down-regulated following RvE1 treatment. These genes may be expressed in the 
disease state to compensate excessive inflammation and down-regulated when the 
inflammation was controlled by RvE1 application (Figs. 3A, 3B). Several genes encoding 
proteins, such as MMPs-3, 10, 13, which are biomarkers for periodontitis in humans, were 
also highly expressed in the rat gingiva with periodontal disease (74–76). The expression of 
these genes was down-regulated by RvE1 treatment. The expression of the genes associated 
with vascularization as well as angiogenesis (Angptl4) (77) and superoxide production as 
well as neutrophil migration (Rac2) (78) were increased in disease and decreased upon 
resolution This was also observed in a human experimental gingivitis study (ANGPTL1) 
(79) and human periodontitis-affected gingiva (RAC2) (80). The gene, Cxcl1, was 
significantly downregulated following RvE1 application in both prevention and treatment 
studies (Figs. 3B, 3C). Cxcl1 is the major chemoattractant of neutrophils in rodents (81, 82) 
and neutrophils are the major cells initiating periodontitis in humans. These results 
demonstrate RvE1 application actions in experimental periodontitis at the molecular level. In 
gene ontology analysis, the genes in the top three significant biological processes (response 
to lipopolysaccharide, response to external stimulus, response to molecules of bacterial 
origin) were downregulated following RvE1 treatment (Supplemental Table I).
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The results also demonstrate that RvE1 regulates the NOD-like receptor signaling pathway 
and the peroxisome proliferator-activated receptor (PPAR) signaling pathway. These two 
pathways have been implicated as important for the inflammatory response in periodontitis 
(83, 84). From the available evidence, RvE1 and other SPMs do not directly regulate NOD-
like receptors or PPARs (85), but indirectly regulate PPAR activity via upstream regulation 
of inflammation (86). Further studies are needed to clarity the role of resolvins in the 
regulation of these two pathways.
Generally, gene expression analyzed by RNA-seq or qRT-PCR is highly correlated, but the 
strength of gene expression fold change, specific genes selected for the analysis, the design 
of primers, and the characteristics of samples may result in discrepancies (87–89). In the 
present study, results of gene expression in RNA-seq and qRT-PCR were well correlated 
(Table II).
The dose-response to RvE1 was most apparent in RNA sequencing experiments. Low dose 
RvE1 might be able to control early-stage inflammation reducing bone resorption (90) and 
inflammatory cell infiltration. Gene expression in gingiva appears to be more sensitive than 
morphometric changes. High dose RvE1 tended to inhibit the growth of bacteria more than 
low dose (Fig. 5). The shifts in subgingival microbiota reflect the change of 
microenvironment. Taken together, there appears to be an optimal dose of RvE1 for treating 
periodontitis.
The data suggest that reduced osteoclast activity following RvE1 application plays an 
important role in controlling alveolar bone loss in this model. It was previously shown that 
RvE1 inhibits osteoclast differentiation in vitro (30) and promotes osteoblast formation in 
vivo (29). In addition, the regeneration of bone following RvE1 treatment likely involves 
enhanced recruitment of non-phlogistic macrophages in the resolution phase given that 
macrophages of the proper phenotype are necessary for tissue regeneration (91, 92). RNA-
seq data demonstrate that bone resorption related pathways are regulated by RvE1, but using 
the KEGG analysis, none of the regeneration related biological pathways or processes were 
significant. Further studies are required to clarify the mechanism of tissue regeneration 
induced by RvE1.
In conclusion, prophylactic RvE1 treatment significantly prevents alveolar bone loss in the 
ligature induced periodontitis model in the rat. The disease associated changes in gene 
expression profile of periodontal tissues is reversed by RvE1 treatment. RvE1 treatment of 
existing ligature induced periodontitis significantly regenerates lost alveolar bone. The shifts 
in the rat subgingival microbiota in experimental periodontitis following RvE1 application 
suggest that inflammation has a significant impact on the local environment and bacterial 
growth conditions. The results suggest that changes in the composition of subgingival 
microbiota emerge as a result of inflammation and fill an important gap in knowledge of the 
actions of RvE1 regulation of the host inflammatory response at the transcriptome level.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RvE1 treatment prevents and reverses alveolar bone loss
(A) Prevention of periodontitis: alveolar bone loss in the disease (vehicle + ligature) group 
prevented by RvE1 (0.1μg/μl). The area of exposed root surface and the distance between 
CEJ and alveolar bone level are outlined. (B) The area of bone loss in mm2 and linear bone 
loss in distance from the CEJ to bone in mm are significantly reduced (~30–40%) in both the 
RvE1 groups (0.1μg/μl) and (0.5μg/μl). (n=4 in the no ligature group, the ligature + vehicle 
group, and the ligature+ RvE1 (0.1μg/μl) group; n=3 in the ligature+RvE1 (0.5μg/μl) group). 
(C) Regeneration of alveolar bone: established periodontitis was treated by topical 
application of RvE1 as a monotherapy. ~30–40% of lost bone was restored with RvE1 
therapy. (D) The area of bone loss in mm2 and linear bone loss in distance from the CEJ to 
bone in mm are significantly reduced (~30–40%) with RvE1 treatment, but alveolar bone 
loss in the vehicle group worsened. (n=6 in the no ligature group and the ligature alone 
group; n=3 in the ligature + vehicle group and the ligature + RvE1 group).
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Figure 2. RvE1 treatment controls osteoclast activity
(A) Osteoclast density was defined as active osteoclast count (TRAP positive multinucleated 
osteoclasts) around the interproximal bone divided by the total area of the interproximal 
bone. Prevention of periodontitis: the osteoclast density in the RvE1 groups (0.1μg/μl) and 
(0.5μg/μl) is significantly lower than the ligature + vehicle group. (n=4 in the no ligature 
group, the ligature + vehicle group, and the ligature+ RvE1 (0.1μg/μl) group; n=3 in the 
ligature+RvE1 (0.5μg/μl) group). (B) Periodontal bone regeneration: RvE1 treatment 
reduced the osteoclast density by 60% compared to the vehicle group and the ligature alone 
group. (n=6 in the no ligature group and the ligature alone group; n=3 in the ligature + 
Vehicle group and the ligature + RvE1 group).
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Figure 3. Impact of RvE1 on Periodontal Gene Expression
(A) A heat map of top 200 differentially expressed genes (absolute log2 fold change) 
compares periodontitis vs. health, Low dose RvE1 (0.1μg/μl) vs. periodontitis, and High 
dose RvE1 (0.5μg/μl) vs. periodontitis. The color intensity reflects the log 2 fold change 
levels for each comparison with red for up- and blue for down-regulation. Genes (in rows) 
were ordered based on the dendrogram derived from hierarchical clustering of log2 values of 
all rows, therefore, genes with similar differential expression patterns were grouped together. 
(B) Genes differentially expressed (mean fold change ≥ 2^0.6, adjusted p-value <0.1) in the 
comparison between disease (ligature + vehicle) and health (no ligature) and between RvE1 
(0.5μg/μl) and disease (ligature+ vehicle). The genes are listed by the order of adjusted p-
value in the comparison between disease and health. The p-values are adjusted using the 
Benjamini–Hochberg procedure. (C) Relative mRNA expression (2−ΔΔCT) was used to 
analyze the gene expression levels of inflammation related genes in different groups. In the 
treatment experiment, gene expression of Cxcl1 in the RvE1 group is significantly lower 
than that in the vehicle group. Gene expression of Ptgs2 in the RvE1 group is significantly 
lower than that in the ligature alone group.
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Figure 4. Shifts in subgingival microbiota associated with periodontal regeneration following 
RvE1 treatment
(A) Mean relative abundance difference between day 0 and day 20 is calculated by 
subtracting mean relative abundance at baseline (day 0) from mean relative abundance at 20 
days post ligature. Positive values indicate the mean relative abundance on day 20 is larger 
than the mean relative abundance on day 0. OTUs that do not match any known genera in the 
reference data base are named at the family level. The most notable changes are the loss of 
Rothia spp. And the overgrowth of Streptococcus spp. as disease develops. (B)(C) Microbial 
shifts associated with the periodontal bone regeneration induced by RvE1 (0.25 μg/ml) 
treatment. Day 32-Panel B and day 40-Panel C are shown. Positive values indicate the mean 
relative abundance of the RvE1 group is larger than the mean relative abundance of the 
Vehicle group. Notably, most of the genera with increased relative abundance after disease 
induction exhibit a trend to return to level more associate with a healthy periodontium. (n=6 
in the no ligature group and the ligature alone group; n=3 in the ligature + Vehicle group and 
the ligature + RvE1 group)”.
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Figure 5. Shifts in subgingival microbiota composition during periodontal disease initiation and 
development
Prevention of periodontitis: shifts in the composition of the microbiota assessed by 16S 
rDNA sequencing were assessed during development of ligature induced periodontitis and 
compared to the low and high doses treatment with RvE1 during disease induction. (A)(B) 
Mean relative abundance difference between the 0.1μg/μl- Panel A, or 0.5μg/μl- Panel B. 
RvE1 treatment and vehicle treated control is calculated by subtracting mean relative 
abundance of the vehicle treatment from mean relative abundance of the RvE1treated doses 
at 14 days post ligature. Positive values indicate the mean relative abundance of the RvE1 
group is larger than the mean relative abundance of the vehicle group. The family name of 
the bacterium is listed for the OTUs that are not assigned to any known genus. (C)(D) Mean 
relative abundance differences on day 28 for the two doses of RvE1 compared to vehicle. 
RvE1 treatment induces major shifts in the subgingival microbiota. Over time, RvE1 
treatment tends to shift the microbiota toward a composition more associated with 
periodontal health. (n=4 in the no ligature group, the ligature + vehicle group, and the 
ligature+ RvE1 (0.1μg/μl) group; n=3 in the ligature+RvE1 (0.5μg/μl) group).
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Table 1
Biological pathways in the two comparisons (Disease vs. Health; RvE1 (0.5μg/μl) vs. Disease)
Disease vs. Health RvE1(0.5μg/ml) vs. Disease
Pathways
False Discovery Rate 
(FDR) Pathways
False 
Discovery 
Rate (FDR)
Phagosome 2.35E-09 *Chemokine signaling pathway 6.98E-05
Lysosome 4.01E-09 Salmonella infection 2.18E-03
Protein digestion and absorption 1.18E-07 TNF signaling pathway 1.03E-02
Hematopoietic cell lineage 3.10E-06
*Chagas disease (American 
trypanosomiasis) 1.03E-02
Tuberculosis 3.88E-05 NOD-like receptor signaling pathway 1.03E-02
*Rheumatoid arthritis 8.20E-05 Legionellosis 1.03E-02
*Chemokine signaling pathway 8.41E-05 PPAR signaling pathway 2.07E-02
Renin-angiotensin system 8.41E-05 *Rheumatoid arthritis 2.07E-02
Leishmaniasis Antigen processing and presentation 8.41E-05 *Bile secretion 3.38E-02
*Osteoclast differentiation 9.69E-05 *Osteoclast differentiation 3.75E-02
ECM-receptor interaction 1.53E-04
Systemic lupus erythematosus 1.54E-04
Staphylococcus aureus infection 2.13E-04
Asthma 2.13E-04
Cytokine-cytokine receptor interaction 3.93E-04
Inflammatory bowel disease (IBD) 7.15E-04
Intestinal immune network for IgA production 1.04E-03
Amoebiasis 1.17E-03
Graft-versus-host disease 1.46E-03
Focal adhesion 1.97E-03
Type I diabetes mellitus 2.39E-03
*Pancreatic secretion 5.28E-03
Leukocyte transendothelial migration 5.82E-03
Autoimmune thyroid disease 6.05E-03
Allograft rejection 6.05E-03
Natural killer cell mediated cytotoxicity 7.68E-03
Herpes simplex infection 8.45E-03
Malaria 9.14E-03
Primary immunodeficiency 1.17E-02
Platelet activation 1.27E-02
PI3K-Akt signaling pathway 1.45E-02
*Chagas disease (American trypanosomiasis) 2.43E-02
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Disease vs. Health RvE1(0.5μg/ml) vs. Disease
Pathways
False Discovery Rate 
(FDR) Pathways
False 
Discovery 
Rate (FDR)
*Bile secretion 2.43E-02
Complement and coagulation cascades 4.41E-02
Platelet activation 1.27E-02
The biological pathways found by using impact analysis are listed by the order of false discovery rate (<0.05).
*
The common pathways are in boldface.
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